<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20DB5C1D-A661-44EB-92D5-F347A3A788FA"><gtr:id>20DB5C1D-A661-44EB-92D5-F347A3A788FA</gtr:id><gtr:name>Magnetic Imaging in Multiple Sclerosis Network (MAGNIMS)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20DB5C1D-A661-44EB-92D5-F347A3A788FA"><gtr:id>20DB5C1D-A661-44EB-92D5-F347A3A788FA</gtr:id><gtr:name>Magnetic Imaging in Multiple Sclerosis Network (MAGNIMS)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/2602FCAF-17D8-4D39-B43C-9F07F879C59B"><gtr:id>2602FCAF-17D8-4D39-B43C-9F07F879C59B</gtr:id><gtr:firstName>Lucy</gtr:firstName><gtr:surname>Matthews</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901996"><gtr:id>10D89287-1B47-4A1B-B4DE-FB3E0AC37FA6</gtr:id><gtr:title>Cross-sectional and Longitudinal MRI Markers of Pathology in Neuromyelitis Optica and Multiple Sclerosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0901996</gtr:grantReference><gtr:abstractText>Neuromyelitis optica (NMO) is a severe neurological condition that damages the myelin insulation that surrounds the nerve fibres in the brain and spinal cord. NMO can cause blindness, paralysis and death. Although there is now an immunological marker for the many NMO cases, we don?t know enough about how the disease progresses over time. There are also several overlapping features of NMO and multiple sclerosis (MS), which also causes damage to myelin, and it can be difficult to differentiate the two conditions. It is important to make the distinction as the treatment for the two conditions is significantly different. 

Using specialised MRI techniques that can detect changes in water molecule motion and chemical constituents within the brain, we aim to find an imaging tool that can identify NMO and distinguish it from MS. This would then allow us to target treatment appropriately. In addition, our high resolution imaging will help to establish how the nerve damage associated with NMO compares with MS (especially as the cause of nerve damage in MS is unknown), and whether there is on-going disease activity even between the relapses. This should be very useful for monitoring treatments in the future.</gtr:abstractText><gtr:technicalSummary>Background: Neuromyelitis optica (NMO) is a severe demyelinating neurological condition of the brain and spinal cord that often results in blindness, quadriplegia and death. Until recently NMO was considered a sub-type of multiple sclerosis (MS), but it is now thought to be a discrete pathological entity supported by the discovery that 70-90% of patients have serum antibodies to aquaporin-4. In contrast to MS it responds to conventional immunosuppression and seems to follow a relapsing course with little recovery. The clinical phenotype is broadening and, in antibody negative cases, may be difficult to classify. The distinction is imperative due to the treatment implications. There are unanswered questions about the pathophysiology of NMO and whether, like MS, background inflammation and neural damage continues between relapses. Prospective longitudinal studies combining conventional and non-conventional MRI to contrast NMO with MS are lacking. 

Aims: 
1. To differentiate NMO brain and spinal cord MRI characteristics from MS (including the use of non-conventional and novel techniques i.e. diffusion tensor imaging (DTI), multi-voxel magnetic resonance spectroscopy (MRS), resting state functional networks and myelin water imaging). 
2. To use longitudinal measures to establish whether NMO is purely a relapsing condition or whether there is ongoing progressive change during the periods of remission (as in MS). 
3. To assess and contrast with MS the anatomical location of the changes, and metabolic and DTI characteristics of lesions 

Lessons learnt from contrasting two inflammatory demyelinating CNS conditions, one antibody-mediated, may also benefit MS research. 

Study Design: Includes a cross-sectional and a longitudinal component using a 3 Tesla field. Four study groups will be compared: a. NMO patients (n=20-25), b. age/sex matched relapsing remitting MS controls (n=20-25), c. age/sex matched healthy controls (n=20-25) and d. patients with MS who are considered borderline for NMO (n?5). A 7 Tesla MRI scan will be performed on a sub-group to investigate the use of this tool in imaging demyelinating lesions. Correlates of MRI indices with clinical and immunological markers will be sort.

Methodology: The MRI brain and spinal cord protocol will include structural imaging (T1, T2, FLAIR), DTI, MRS and myelin water imaging. MRI data will be analysed for volumetric measures, voxel wise diffusion indices and biochemical content, and resting networks. 

Opportunities: This study will investigate the role of MRI in the diagnosis and monitoring of NMO, and inform on the pathological processes in-vivo with particular reference to multiple sclerosis, the aetiology of which remains unknown.</gtr:technicalSummary><gtr:fund><gtr:end>2012-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>144646</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Human Immunology Unit</gtr:department><gtr:description>Neuroprotection in primary progressive MS</gtr:description><gtr:id>A07A562A-3D69-48A1-A227-96AD9F4DF746</gtr:id><gtr:impact>The following abstract was presented at the 2011 ECTRIMS Meeting: Acid-sensing ion channel 1 blockade preserves brain microstructural integrity in patients with multiple sclerosis. Multiple Sclerosis Journal 2011: 17: S205:P484.
This research is currently being prepared for publication.</gtr:impact><gtr:outcomeId>QPGo4sjtNwX-1</gtr:outcomeId><gtr:piContribution>I have contributed my imaging expertise in the trial of a potential neuroprotective agent for primary progressive MS.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Magnetic Imaging in Multiple Sclerosis Network (MAGNIMS)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Collaboration with MAGNIMS (Magnetic Imaging in Multiple Sclerosis) network</gtr:description><gtr:id>2CE13CBD-4054-4862-B211-1811C169588B</gtr:id><gtr:impact>Data I contributed to this collaboration was presented in the 2011 ECTRIMS prize winning poster. 
See abstract in Multiple Sclerosis Journal 2011;17:S147:P366: Brain Atrophy in MS: long-term predictive value.</gtr:impact><gtr:outcomeId>QA9UVEuYPGQ-1</gtr:outcomeId><gtr:partnerContribution>This collaborative network have contributed MRI data from patients with the rare neurological condition Leber's Hereditary Optic Neuropathy for my research study.</gtr:partnerContribution><gtr:piContribution>We meet twice yearly to discuss current research, and contribute MRI data to one another to strengthen research studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Psychiatry, Psychology &amp; Neuroscience</gtr:department><gtr:description>Myelin Water Imaging Collaboration</gtr:description><gtr:id>A0BB9FFB-D16F-47EC-B316-4C868DB68322</gtr:id><gtr:impact>We recently had a paper accepted by Neuroimage, which presents the application of myelin imaging to a group of primary progressive MS patients (Ms. No.: NIMG-11-2177R1 Title: Myelin Water Imaging Reflects Clinical Variability in Multiple Sclerosis).
I have also presented the results of the application of this technique at international conferences including ECTRIMS 2011 (Multiple Sclerosis Journal 2011: 17:S165:P402: Matthews L. et al. Distinction of aquaporin-4 antibody positive neuromyelitis optica from multiple sclerosis using diffusion tensor and myelin water imaging), and the Association of British Neurologists 2010 (Matthews L, et al. Comparing MRI measures of myelin integrity as surrogate markers for the clinical expression of primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 81(11):e56 (2010)).</gtr:impact><gtr:outcomeId>jexXK3ms8iZ-1</gtr:outcomeId><gtr:partnerContribution>I work closely with a physicist who has developed a new technique for quantifying myelin density using MRI. I have applied this to neuromyelitis optica in my research study, with interesting results.</gtr:partnerContribution><gtr:piContribution>I have supported the development of a new MRI technique by providing a clinical application.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School Visit. Woodstock.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F5AEBDCF-2B98-49AC-9F52-5D8E120FAAE7</gtr:id><gtr:impact>I spoke to twenty students who were due to be applying for university courses later in the year. I gave an interactive talk about MRI physics and its medical applications with particular reference to my study. The level of interest was high and there were several questions about medical and science careers.

I have since learnt that two of the students have applied for medical school and several for science courses.</gtr:impact><gtr:outcomeId>JSPBcM1JmkB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Brain Awareness Week</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>314A43A2-359F-4E94-97F3-C2B8B5D27F20</gtr:id><gtr:impact>Presentation to primary school children about brain function and neurological problems for Brain Awareness Week 2012.

Feedback very good. Asked to repeat talk for a further school group.</gtr:impact><gtr:outcomeId>DfaE3hT3ieS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to a patient group. Banbury MS Society.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E56F62C3-F81B-477E-BDA2-AA0F50EF7FBE</gtr:id><gtr:impact>I spoke to approximately fifty MS patients and their relatives at the Annual Group Meeting of the Banbury branch of the MS Society. I gave a talk about MRI and its medical applications with reference to my study.

There was a lot of interest in the study, many questions and several patients have inquired about participating in MRI studies within the FMRIB laboratory.</gtr:impact><gtr:outcomeId>SZ33NKRpjNL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Neuromyelitis Optica Patient Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1D194B10-02FB-45A9-9378-89BEFBB546AF</gtr:id><gtr:impact>100 patient and relatives attended the talk about the MRI research study that I am currently running. The audience was very interested, there were many questions and it led to further subject recruitment.

Further subject recruitment for the MRI research study.</gtr:impact><gtr:outcomeId>Lbm7J72NWuc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>105049</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Guthy Jackson Foundation</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Guthy-Jackson?Charitable?Foundation</gtr:fundingOrg><gtr:id>B317737E-E14A-449B-BF00-FA9DA4BDDAE7</gtr:id><gtr:outcomeId>jmgtz9ocBTd</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7117</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>John Fell Fund</gtr:department><gtr:description>University of Oxford John Fell Fund</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>B3DE86A3-1052-4280-AF27-88E5A6D8CB02</gtr:id><gtr:outcomeId>psNFFNck6xa0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Travel Bursary</gtr:description><gtr:end>2011-10-02</gtr:end><gtr:fundingOrg>European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)</gtr:fundingOrg><gtr:id>0B297009-E01C-42EC-8F6D-C6CDB22C79CA</gtr:id><gtr:outcomeId>neZCHsXTZ4T</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Travel award</gtr:description><gtr:end>2012-10-02</gtr:end><gtr:fundingOrg>European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)</gtr:fundingOrg><gtr:id>311D0E8E-6487-49AF-B34F-5D58F689B76E</gtr:id><gtr:outcomeId>PqEks4zFoQD</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>090B4CAB-44EE-40F4-818C-2A746F1449CC</gtr:id><gtr:title>Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/430ff574c1983d13c6664f0670907bba"><gtr:id>430ff574c1983d13c6664f0670907bba</gtr:id><gtr:otherNames>Matthews L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675ebb491479</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE735CC6-D3CD-4457-83C7-3A1C350B1A5F</gtr:id><gtr:title>Multi-modal characterization of rapid anterior hippocampal volume increase associated with aerobic exercise.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6630ddda0b4d83599f21e689f718177"><gtr:id>d6630ddda0b4d83599f21e689f718177</gtr:id><gtr:otherNames>Thomas AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>58c71fdde7c658.39925693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3209D54-4001-418E-BDB1-B3C2DB0B3082</gtr:id><gtr:title>Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d62528515323b140c0b7f1efac5703d3"><gtr:id>d62528515323b140c0b7f1efac5703d3</gtr:id><gtr:otherNames>Jurynczyk M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>58c71fdd988d32.60541366</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC8DA300-02B0-422F-A914-4502DE40E947</gtr:id><gtr:title>Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/430ff574c1983d13c6664f0670907bba"><gtr:id>430ff574c1983d13c6664f0670907bba</gtr:id><gtr:otherNames>Matthews L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_16590_20_23486868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF6DA7D8-FD8D-44F0-96B3-DA60BA195253</gtr:id><gtr:title>Brain atrophy and lesion load predict long term disability in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c53a3a94cec146279c3b010396ba30a0"><gtr:id>c53a3a94cec146279c3b010396ba30a0</gtr:id><gtr:otherNames>Popescu V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>pm_16590_20_23524331</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>84781D61-38D5-4325-8D24-298AECF9AD74</gtr:id><gtr:title>The borderland of neuromyelitis optica.</gtr:title><gtr:parentPublicationTitle>Practical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb1c973c41f194c6e3c885e0a982a7bf"><gtr:id>cb1c973c41f194c6e3c885e0a982a7bf</gtr:id><gtr:otherNames>Matthews LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1474-7758</gtr:issn><gtr:outcomeId>U7xPUzyEkb6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68982A3A-FAEC-4907-9893-5689C7B8255B</gtr:id><gtr:title>Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa0b6ef76225dc642b86c7e03e3cfd59"><gtr:id>aa0b6ef76225dc642b86c7e03e3cfd59</gtr:id><gtr:otherNames>Rodr?guez Cruz PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>58c71fddc16b34.69430425</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>14BAE4F9-5DCC-479C-811A-8CACAAC79AC2</gtr:id><gtr:title>Use of mitoxantrone in neuromyelitis optica.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ae2c843568e2225b82d1e0beba28e65"><gtr:id>1ae2c843568e2225b82d1e0beba28e65</gtr:id><gtr:otherNames>Kitley JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>QEdRFXeyKW9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5537766F-5C5F-4EFF-BFF9-365B3B647F05</gtr:id><gtr:title>Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9dae4a004efebd5e873710e47bdf13ae"><gtr:id>9dae4a004efebd5e873710e47bdf13ae</gtr:id><gtr:otherNames>Arun T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_16590_20_23365093</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28836FD5-E35E-40E8-B2C4-4DB3752BEB7B</gtr:id><gtr:title>Structural imaging of the cervical spinal cord with suppressed CSF signal using DANTE pulse trains.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cd97b4a1e149c4f95df16a9cd3b6324"><gtr:id>0cd97b4a1e149c4f95df16a9cd3b6324</gtr:id><gtr:otherNames>Li L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>5463d2e0917718.17252811</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5972640-7EEC-4DE4-B7C2-3925F034340E</gtr:id><gtr:title>Low myo-inositol indicating astrocytic damage in a case series of neuromyelitis optica.</gtr:title><gtr:parentPublicationTitle>Annals of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70612e26e36d097fbdd9556fd56df1a7"><gtr:id>70612e26e36d097fbdd9556fd56df1a7</gtr:id><gtr:otherNames>Ciccarelli O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0364-5134</gtr:issn><gtr:outcomeId>pm_16590_20_23553900</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E5BA313-6323-444E-BBD3-A315176EA361</gtr:id><gtr:title>MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis</gtr:title><gtr:parentPublicationTitle>Journal of Neurology, Neurosurgery &amp; Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/430ff574c1983d13c6664f0670907bba"><gtr:id>430ff574c1983d13c6664f0670907bba</gtr:id><gtr:otherNames>Matthews L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn><gtr:outcomeId>5463d2e0b97ee0.36886640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CACE913-1D88-48AA-BCA2-1FA849F04DEC</gtr:id><gtr:title>Myelin water imaging reflects clinical variability in multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/101bf71c975bd01cb8c440f2b356903e"><gtr:id>101bf71c975bd01cb8c440f2b356903e</gtr:id><gtr:otherNames>Kolind S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>pm_16590_20_22155325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>436AC7CC-3575-4C8D-890D-6FBA87358BE4</gtr:id><gtr:title>Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder.</gtr:title><gtr:parentPublicationTitle>NeuroImage. Clinical</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6608a1fa8ce5ddd2a27cd767aad85068"><gtr:id>6608a1fa8ce5ddd2a27cd767aad85068</gtr:id><gtr:otherNames>Combes AJE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-1582</gtr:issn><gtr:outcomeId>5aaa4d0251af79.57400281</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59BA958B-394F-4F34-BF15-7164AED8E4D9</gtr:id><gtr:title>A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77ed1262063e9329e3175cc70758d0fa"><gtr:id>77ed1262063e9329e3175cc70758d0fa</gtr:id><gtr:otherNames>Dickens AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5463d2e0670dc7.31612801</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F974FFB3-2594-4627-8681-FEBA8EE01066</gtr:id><gtr:title>The role of imaging in diagnosing neuromyelitis optica spectrum disorder.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis and related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb1c973c41f194c6e3c885e0a982a7bf"><gtr:id>cb1c973c41f194c6e3c885e0a982a7bf</gtr:id><gtr:otherNames>Matthews LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2211-0348</gtr:issn><gtr:outcomeId>5463d6cb639658.45437410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0AD240B-821E-48D2-949A-04C8538768E0</gtr:id><gtr:title>One component? Two components? Three? The effect of including a nonexchanging &amp;quot;free&amp;quot; water component in multicomponent driven equilibrium single pulse observation of T1 and T2.</gtr:title><gtr:parentPublicationTitle>Magnetic resonance in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/601d04bcf6c118259793ab6de2280adc"><gtr:id>601d04bcf6c118259793ab6de2280adc</gtr:id><gtr:otherNames>Deoni SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0740-3194</gtr:issn><gtr:outcomeId>pm_16590_20_22915316</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901996</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>